Patent: 10,590,182
✉ Email this page to a colleague
Summary for Patent: 10,590,182
| Title: | Binding-triggered transcriptional switches and methods of use thereof |
| Abstract: | The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided. |
| Inventor(s): | Lim; Wendell A. (San Francisco, CA), Morsut; Leonardo (San Francisco, CA), Roybal; Kole T. (San Francisco, CA), Farlow; Justin Thomas (San Francisco, CA), Toda; Satoshi (San Francisco, CA) |
| Assignee: | The Regents of the University of California (Oakland, CA) |
| Application Number: | 15/543,220 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,590,182
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | December 22, 1994 | ⤷ Subscribe | 2035-02-24 |
| Aytu Bioscience, Inc. | PROSTASCINT | capromab pendetide | Injection | 103608 | October 28, 1996 | ⤷ Subscribe | 2035-02-24 |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | ⤷ Subscribe | 2035-02-24 |
| Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | December 10, 1997 | ⤷ Subscribe | 2035-02-24 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | May 12, 1998 | ⤷ Subscribe | 2035-02-24 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | January 02, 2003 | ⤷ Subscribe | 2035-02-24 |
| Boehringer Ingelheim Pharma Gmbh & Co. Kg | VERLUMA | nofetumomab | Injection | 103769 | October 13, 1998 | ⤷ Subscribe | 2035-02-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
